Santaris Pharma, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has announced that its long-term partner, Shire, has extended the existing partnership in the rare genetic disease space.  

Shire will have the right to nominate additional collaboration targets for drug discovery and development. Santaris will receive an upfront payment and, consistent with the initial agreement, is eligible for research support, preclinical, clinical and sales milestones and royalties on each product emerging from the collaboration.